Gastroenterology and Hepatology最新文献_第3页

Approach to Meal-Related Nausea and Vomiting.

Gastroenterology and Hepatology Pub Date : 2025-01-01

David J Cangemi, R Christopher Chase, Brian E Lacy

{"title":"Approach to Meal-Related Nausea and Vomiting.","authors":"David J Cangemi, R Christopher Chase, Brian E Lacy","doi":"","DOIUrl":"","url":null,"abstract":"Nausea and vomiting are common symptoms that frequently lead to evaluation in the outpatient and inpatient settings. The pathophysiology of nausea and vomiting is complex, and the list of potential etiologies is vast. Patients with nausea and vomiting frequently report that eating exacerbates symptoms. Noteworthy gastrointestinal causes for meal-related nausea and vomiting include gastroparesis, functional dyspepsia, dumping syndrome, superior mesenteric artery syndrome, and median arcuate ligament syndrome. A number of carefully selected diagnostic tests, utilization of the Rome criteria, and an appreciation for the epidemiology of these various conditions can help the clinician hone in on the underlying cause. Importantly, a properly performed and interpreted gastric emptying study is essential to making an accurate diagnosis of gastroparesis and distinguishing this condition from functional dyspepsia, a common disorder of gut-brain interaction. There are a number of treatment options for nausea and vomiting, and the treatment approach is dependent on the specific cause for the meal-related symptoms. This article examines the approach to meal-related nausea and vomiting by reviewing tests to consider in the diagnostic evaluation of symptoms, followed by a discussion of clinically relevant disorders and disorder-specific treatments.","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 1","pages":"19-27"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient-Provider Communication: The Key to Improving IBS-C Management.

Gastroenterology and Hepatology Pub Date : 2025-01-01

Christina Hanson

引用次数: 0

New Approaches and Old Struggles in Antireflux Endoscopy.

Gastroenterology and Hepatology Pub Date : 2025-01-01

Nikhil A Kumta

引用次数: 0

Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Inflammatory Bowel Disease.

Gastroenterology and Hepatology Pub Date : 2025-01-01

Christine Boumitri

引用次数: 0

Navigating Chronic Pouchitis: Pathogenesis, Diagnosis, and Management.

Gastroenterology and Hepatology Pub Date : 2025-01-01

Robert Hill, Simon Travis, Zaid Ardalan

引用次数: 0

Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Compensated Cirrhosis in the Phase 3 Placebo-Controlled RESPONSE Trial.

Gastroenterology and Hepatology Pub Date : 2024-12-01

引用次数: 0

Efficacy and Safety of Plecanatide in Treatment of Irritable Bowel Syndrome With Constipation and Chronic Idiopathic Constipation.

Gastroenterology and Hepatology Pub Date : 2024-12-01

引用次数: 0

Are All Esophageal Ulcers Caused by Gastroesophageal Reflux Disease?

Gastroenterology and Hepatology Pub Date : 2024-12-01

Nayantara Coelho-Prabhu

引用次数: 0

Potassium-Competitive Acid Blockers and Proton Pump Inhibitors: The Dynamic Duo of Acid Blockers.

Gastroenterology and Hepatology Pub Date : 2024-12-01

Corey J Ketchem, Kristle L Lynch

{"title":"Potassium-Competitive Acid Blockers and Proton Pump Inhibitors: The Dynamic Duo of Acid Blockers.","authors":"Corey J Ketchem, Kristle L Lynch","doi":"","DOIUrl":"","url":null,"abstract":"The management of acid-based disorders was transformed in the 1980s with the advent of proton pump inhibitors (PPIs), which target the hydrogen-potassium adenosine triphosphatase (proton pump) of the parietal cell. Potassium-competitive acid blockers (P-CABs), a newer class of medications, act at the same proton pump through a novel mechanism resulting in profound and sustained acid suppression. Although trials in Asian populations over the past decades have highlighted the potential benefit of P-CABs, clinical trials in Western populations have been initiated more recently. These trials evaluated vonoprazan in patients with Helicobacter pylori infection, erosive esophagitis, and heartburn with nonerosive reflux disease and have demonstrated promising results, culminating in US Food and Drug Administration approval for these indications. Adverse event profiles between PPIs and P-CABs appear comparable thus far, although additional long-term data on P-CABs are needed. While navigating the evolving landscape of acid suppression, it is crucial to identify which patients and diseases are poised to derive the most benefit from this emerging therapeutic option. This article seeks to highlight important pharmacologic properties of PPIs and P-CABs, understand the current literature with a focus on clinical trials in Western populations, and explore potential scenarios for integrating P-CABs into therapeutic regimens.","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12","pages":"733-738"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety of Long-Term Ozanimod Treatment Up to 5 Years in Patients With Moderately to Severely Active Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension.

Gastroenterology and Hepatology Pub Date : 2024-12-01

引用次数: 0